Wall Street brokerages expect Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) to post earnings per share of ($0.33) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Y-mAbs Therapeutics’ earnings. The highest EPS estimate is ($0.30) and the lowest is ($0.36). The firm is scheduled to announce its next quarterly earnings report on Tuesday, February 12th.
According to Zacks, analysts expect that Y-mAbs Therapeutics will report full year earnings of ($1.41) per share for the current year, with EPS estimates ranging from ($1.44) to ($1.38). For the next year, analysts expect that the company will post earnings of ($1.37) per share, with EPS estimates ranging from ($1.49) to ($1.25). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Y-mAbs Therapeutics.
Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings data on Tuesday, November 13th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.09).
Y-mAbs Therapeutics stock traded down $0.74 during mid-day trading on Monday, reaching $22.63. 100,609 shares of the company traded hands, compared to its average volume of 59,102. Y-mAbs Therapeutics has a 52-week low of $18.00 and a 52-week high of $31.00.
In other Y-mAbs Therapeutics news, Director Ashu Tyagi bought 430,174 shares of the company’s stock in a transaction dated Tuesday, September 25th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $6,882,784.00. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Moller San Pedro Claus Juan bought 31,250 shares of the company’s stock in a transaction dated Tuesday, September 25th. The shares were acquired at an average price of $16.00 per share, for a total transaction of $500,000.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 961,424 shares of company stock worth $15,382,784.
Hedge funds have recently made changes to their positions in the company. Artal Group S.A. bought a new stake in shares of Y-mAbs Therapeutics during the 3rd quarter valued at $3,984,000. Monashee Investment Management LLC bought a new position in Y-mAbs Therapeutics in the 3rd quarter worth about $1,801,000. Dean Capital Investments Management LLC bought a new position in Y-mAbs Therapeutics in the 3rd quarter worth about $664,000. Scopia Capital Management LP bought a new position in Y-mAbs Therapeutics in the 3rd quarter worth about $42,166,000. Finally, Man Group plc bought a new position in Y-mAbs Therapeutics in the 3rd quarter worth about $1,063,000. Hedge funds and other institutional investors own 22.38% of the company’s stock.
Y-mAbs Therapeutics Company Profile
Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.